(19)
(11)EP 3 040 347 A3

(12)EUROPEAN PATENT APPLICATION

(88)Date of publication A3:
21.09.2016 Bulletin 2016/38

(43)Date of publication A2:
06.07.2016 Bulletin 2016/27

(21)Application number: 16152989.6

(22)Date of filing:  19.10.2007
(51)International Patent Classification (IPC): 
C07K 16/22(2006.01)
A61P 35/00(2006.01)
C12N 15/09(2006.01)
A61K 39/395(2006.01)
C07K 16/24(2006.01)
C12P 21/08(2006.01)
(84)Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

(30)Priority: 20.10.2006 JP 2006286824
16.04.2007 JP 2007107207

(62)Application number of the earlier application in accordance with Art. 76 EPC:
07830221.3 / 2078731

(71)Applicant: Chugai Seiyaku Kabushiki Kaisha
Kita-ku Tokyo 115-8543 (JP)

(72)Inventor:
  • KIMURA, Naoki
    Tokyo 153-0041 (JP)

(74)Representative: Power, David 
J A Kemp 14 South Square Gray's Inn
London WC1R 5JJ
London WC1R 5JJ (GB)

  


(54)PHARMACEUTICAL COMPOSITION COMPRISING ANTI-HB-EGF ANTIBODY AS ACTIVE INGREDIENT


(57) An anti-HB-EGF antibody having an internalizing activity is disclosed. A cytotoxic substance is preferably bound to the anti-HB-EGF antibody of the present invention. Also provided are an anti-cancer agent and a cell proliferation inhibitor, which comprise the antibody of the present invention as an active ingredient, a method of treating cancer and a method of diagnosing cancer, which comprise the administration of the antibody of the present invention. Cancers that can be treated by the anti-cancer agent of the present invention include pancreatic cancer, liver cancer, esophageal cancer, melanoma, colorectal cancer, gastric cancer, ovarian cancer, uterine cervical cancer, breast cancer, bladder cancer, brain tumors, and hematological cancers.





Search report
























Search report